FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

Researchers at Moffitt Cancer Center are studying DYV800, a topical cream designed to reduce tumor acidity and help the ...

FDA cleared oral decitabine/cedazuridine plus venetoclax for frontline AML in adults ≥75 years or with comorbidities that make intensive induction inappropriate. Study ASTX727-07 (single-arm, ...

A USC study finds immunotherapy increases PAD risk by 60%. Experts advise vascular monitoring to help prevent limb loss in ...

Although the oncology community is buzzing with the potential of circulating tumor DNA (ctDNA) to revolutionize breast cancer ...

Dr. Susan MacDonald breaks down the TNM staging system (Tumor, Nodes, Metastasis) to help patients understand their clinical ...

Researchers at Moffitt Cancer Center are studying DYV800, a topical cream designed to reduce tumor acidity and help the immune system fight cancer.

Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.

Sharing survivorship narratives over years functioned as peer-to-peer hope provision for others confronting breast cancer or ...

SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the ...

Patients welcome subcutaneous immunotherapy for shorter clinic time, with the same monitoring—reshaping expectations of cancer care. This segment focuses on how patients with advanced melanoma ...

Molecular/genomic profiling is expanding precision selection of systemic therapy and may enable immunotherapy-driven organ ...